文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

JAK2-V617F与干扰素-α诱导偏巨核分化的造血干细胞及其长期功能下降

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
PubMed 文献 · Blood · 2021-01-01

研究聚焦CD41高表达(CD41hi)的造血干细胞亚群,发现其偏巨核分化。JAK2-V617F小鼠及MPN患者骨髓中CD41hi HSC频率和比例增加,且与突变等位基因负荷相关。CD41hi HSC体外产巨核集落增多但长期重建潜能降低。干扰素-α进一步增加CD41hi HSC并减少JAK2-V617F+ HSC,可能解释其优先靶向突变克隆的机制。

要点

  • MPN中CD41hi HSC扩增且与JAK2-V617F突变负荷相关。
  • CD41hi HSC偏巨核分化但长期造血重建能力下降。
  • 干扰素-α增加CD41hi HSC并减少JAK2-V617F+ HSC。

核心结论

  • JAK2-V617F与干扰素-α可诱导偏巨核分化的CD41hi HSC,该亚群长期功能下降,可能解释干扰素-α优先靶向突变克隆。

研究设计与样本

  • 研究采用JAK2-V617F表达的小鼠MPN模型与MPN患者骨髓样本,结合体外单细胞培养和体内竞争性移植实验。

主要发现

  • JAK2-V617F小鼠CD41hi HSC频率和比例较野生型对照增加。
  • MPN患者骨髓CD41hi HSC增加且与JAK2-V617F突变等位基因负荷相关。
  • CD41hi HSC体外单细胞培养产巨核集落数高于CD41lo HSC。
  • CD41hi HSC在竞争性移植中长期重建潜能低于CD41lo HSC。
  • CD41hi HSC中细胞周期、Myc和氧化磷酸化基因签名上调,且细胞周期活性与活性氧水平升高。

临床怎么用

  • 监测CD41hi HSC比例及JAK2-V617F突变负荷可能有助于理解MPN克隆演变。
  • 干扰素-α治疗通过增加CD41hi HSC并减少JAK2-V617F+ HSC发挥优先靶向突变克隆的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We studied a subset of hematopoietic stem cells (HSCs) that are defined by elevated expression of CD41 (CD41hi) and showed bias for differentiation toward megakaryocytes (Mks). Mouse models of myeloproliferative neoplasms (MPNs) expressing JAK2-V617F (VF) displayed increased frequencies and percentages of the CD41hi vs CD41lo HSCs compared with wild-type controls. An increase in CD41hi HSCs that correlated with JAK2-V617F mutant allele burden was also found in bone marrow from patients with MPN. CD41hi HSCs produced a higher number of Mk-colonies of HSCs in single-cell cultures in vitro, but showed reduced long-term reconstitution potential compared with CD41lo HSCs in competitive transplantations in vivo. RNA expression profiling showed an upregulated cell cycle, Myc, and oxidative phosphorylation gene signatures in CD41hi HSCs, whereas CD41lo HSCs showed higher gene expression of interferon and the JAK/STAT and TNFα/NFκB signaling pathways. Higher cell cycle activity and elevated levels of reactive oxygen species were confirmed in CD41hi HSCs by flow cytometry. Expression of Epcr, a marker for quiescent HSCs inversely correlated with expression of CD41 in mice, but did not show such reciprocal expression pattern in patients with MPN. Treatment with interferon-α further increased the frequency and percentage of CD41hi HSCs and reduced the number of JAK2-V617F+ HSCs in mice and patients with MPN. The shift toward the CD41hi subset of HSCs by interferon-α provides a possible mechanism of how interferon-α preferentially targets the JAK2 mutant clone.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rao TN, Hansen N, Stetka J, et al. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021. PMID: 33667305. doi:10.1182/blood.2020005563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。